Surgical management of recurrent ovarian cancer

Dong Hoon Suh, Hee Seung Kim, Suk Joon Chang, Robert E. Bristow

Research output: Contribution to journalArticle

Abstract

Most patients with advanced-stage epithelial ovarian cancer will experience a relapse of disease despite a complete response after surgical cytoreduction and platinum-based chemotherapy. Treatment of recurrent ovarian cancer mainly comprises various combinations of systemic chemotherapy with or without targeted agents. The role of cytoreductive surgery for recurrent ovarian cancer is not well established. Although the literature on survival benefit of cytoreductive surgery for recurrent disease has expanded steadily over the past decade, most studies were retrospective, single-institution series with small numbers of patients. Given the balance between survival benefit and surgery-related morbidity during maximum cytoreductive surgical effort, it is essential to establish the optimal selection criteria for identifying appropriate candidates who will benefit from surgery without worsening quality of life. Three phase III randomized trials for this issue are currently underway. Herein, we present contemporary evidence supporting the positive role of cytoreductive surgery and offer selection criteria for optimal candidates for surgery in the treatment of recurrent ovarian cancer.

Original languageEnglish (US)
JournalGynecologic Oncology
DOIs
StateAccepted/In press - Feb 17 2016
Externally publishedYes

Fingerprint

Ovarian Neoplasms
Patient Selection
Survival
Combination Drug Therapy
Platinum
Retrospective Studies
Quality of Life
Morbidity
Recurrence
Drug Therapy
Therapeutics

Keywords

  • Cytoreductive surgery
  • Recurrent ovarian cancer
  • Selection criteria

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Suh, D. H., Kim, H. S., Chang, S. J., & Bristow, R. E. (Accepted/In press). Surgical management of recurrent ovarian cancer. Gynecologic Oncology. https://doi.org/10.1016/j.ygyno.2016.04.537

Surgical management of recurrent ovarian cancer. / Suh, Dong Hoon; Kim, Hee Seung; Chang, Suk Joon; Bristow, Robert E.

In: Gynecologic Oncology, 17.02.2016.

Research output: Contribution to journalArticle

Suh, Dong Hoon ; Kim, Hee Seung ; Chang, Suk Joon ; Bristow, Robert E. / Surgical management of recurrent ovarian cancer. In: Gynecologic Oncology. 2016.
@article{2a53ac5c76ab4ebeac1547a7d4a0c59b,
title = "Surgical management of recurrent ovarian cancer",
abstract = "Most patients with advanced-stage epithelial ovarian cancer will experience a relapse of disease despite a complete response after surgical cytoreduction and platinum-based chemotherapy. Treatment of recurrent ovarian cancer mainly comprises various combinations of systemic chemotherapy with or without targeted agents. The role of cytoreductive surgery for recurrent ovarian cancer is not well established. Although the literature on survival benefit of cytoreductive surgery for recurrent disease has expanded steadily over the past decade, most studies were retrospective, single-institution series with small numbers of patients. Given the balance between survival benefit and surgery-related morbidity during maximum cytoreductive surgical effort, it is essential to establish the optimal selection criteria for identifying appropriate candidates who will benefit from surgery without worsening quality of life. Three phase III randomized trials for this issue are currently underway. Herein, we present contemporary evidence supporting the positive role of cytoreductive surgery and offer selection criteria for optimal candidates for surgery in the treatment of recurrent ovarian cancer.",
keywords = "Cytoreductive surgery, Recurrent ovarian cancer, Selection criteria",
author = "Suh, {Dong Hoon} and Kim, {Hee Seung} and Chang, {Suk Joon} and Bristow, {Robert E.}",
year = "2016",
month = "2",
day = "17",
doi = "10.1016/j.ygyno.2016.04.537",
language = "English (US)",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Surgical management of recurrent ovarian cancer

AU - Suh, Dong Hoon

AU - Kim, Hee Seung

AU - Chang, Suk Joon

AU - Bristow, Robert E.

PY - 2016/2/17

Y1 - 2016/2/17

N2 - Most patients with advanced-stage epithelial ovarian cancer will experience a relapse of disease despite a complete response after surgical cytoreduction and platinum-based chemotherapy. Treatment of recurrent ovarian cancer mainly comprises various combinations of systemic chemotherapy with or without targeted agents. The role of cytoreductive surgery for recurrent ovarian cancer is not well established. Although the literature on survival benefit of cytoreductive surgery for recurrent disease has expanded steadily over the past decade, most studies were retrospective, single-institution series with small numbers of patients. Given the balance between survival benefit and surgery-related morbidity during maximum cytoreductive surgical effort, it is essential to establish the optimal selection criteria for identifying appropriate candidates who will benefit from surgery without worsening quality of life. Three phase III randomized trials for this issue are currently underway. Herein, we present contemporary evidence supporting the positive role of cytoreductive surgery and offer selection criteria for optimal candidates for surgery in the treatment of recurrent ovarian cancer.

AB - Most patients with advanced-stage epithelial ovarian cancer will experience a relapse of disease despite a complete response after surgical cytoreduction and platinum-based chemotherapy. Treatment of recurrent ovarian cancer mainly comprises various combinations of systemic chemotherapy with or without targeted agents. The role of cytoreductive surgery for recurrent ovarian cancer is not well established. Although the literature on survival benefit of cytoreductive surgery for recurrent disease has expanded steadily over the past decade, most studies were retrospective, single-institution series with small numbers of patients. Given the balance between survival benefit and surgery-related morbidity during maximum cytoreductive surgical effort, it is essential to establish the optimal selection criteria for identifying appropriate candidates who will benefit from surgery without worsening quality of life. Three phase III randomized trials for this issue are currently underway. Herein, we present contemporary evidence supporting the positive role of cytoreductive surgery and offer selection criteria for optimal candidates for surgery in the treatment of recurrent ovarian cancer.

KW - Cytoreductive surgery

KW - Recurrent ovarian cancer

KW - Selection criteria

UR - http://www.scopus.com/inward/record.url?scp=84975122026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975122026&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2016.04.537

DO - 10.1016/j.ygyno.2016.04.537

M3 - Article

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

ER -